US 12,247,076 B2
Use of modified Fc fragments in immunotherapy
Philippe Mondon, Neuve Chapelle (FR); Céline Monnet-Mars, Lambersart (FR); Alexandre Fontayne, La Madeleine (FR); Christophe De Romeuf, Lambersart (FR); and Abdessatar Chtourou, Elancourt (FR)
Assigned to Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis (FR)
Appl. No. 15/742,268
Filed by Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis (FR)
PCT Filed Jul. 6, 2016, PCT No. PCT/FR2016/051708
§ 371(c)(1), (2) Date Jan. 5, 2018,
PCT Pub. No. WO2017/006052, PCT Pub. Date Jan. 12, 2017.
Claims priority of application No. 1556399 (FR), filed on Jul. 6, 2015.
Prior Publication US 2018/0355034 A1, Dec. 13, 2018
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/283 (2013.01) [A61K 39/0008 (2013.01); A61K 39/001 (2013.01); A61P 37/06 (2018.01); C07K 16/00 (2013.01); A61K 2039/55 (2013.01); C07K 2317/52 (2013.01); C07K 2317/70 (2013.01); C07K 2317/94 (2013.01)] 8 Claims
 
1. A method for treating an autoimmune disease in a subject, the method comprising administering an antibody Fc fragment composition to the subject, wherein said antibody Fc fragment composition comprises isolated Fc fragments having an improved affinity for FcγRIII receptor (CD16a) by a ratio of at least 2 as compared to a parent Fc fragment, and wherein the Fc fragments comprise a combination of mutations K334N/P352S/A378V/V397M in comparison with the parent Fc fragment,
wherein the parent Fc fragment is the Fc fragment of wild-type IgG1 of SEQ ID NO:6, wherein the numbering of the Fc fragment amino acids refers to that of the EU index or the Kabat equivalent, and wherein the autoimmune disease is selected from the group consisting of idiopathic thrombotic purpura, chronic demyelinating inflammatory polyradiculoneuropathy (CDIP), and myasthenia gravis.